Olopatadine HCL 0.1% Ophthalmic Solution
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Logistics Agency (DLA) Troop Support has awarded a contract (SPE2D2-23-D-0007) for Olopatadine HCL 0.1% Ophthalmic Solution (5ML bottles). This contract, initially valued at an estimated $17.6 million over five years, has undergone multiple modifications. The most recent significant change (P00011) updates the manufacturer to SamChunDang Pharm Co., Ltd. and shifts the place of performance for manufacturing to Korea, effective June 1, 2026, along with a new National Drug Code (NDC).
Contract Overview
- Contract Number: SPE2D2-23-D-0007
- Award Date: February 15, 2023
- Type: Award Notice (likely IDIQ with option years)
- Duration: Base Year + 4 Option Years (Option Years 1, 2, and 3 have been exercised, extending performance through February 14, 2027).
- Estimated Value: $17,621,453.20 over 5 years ($3,524,290.64 annually).
- Set-Aside: The original solicitation indicated a focus on Small Business Participation, including HUBZone, Service-Disabled Veteran-Owned Small Business, and Women-Owned Small Business concerns.
- Product/Service Code: 6505 - Drugs And Biologicals
Scope of Product
This contract is for the procurement of Olopatadine HCL 0.1% Ophthalmic Solution in 5ML bottles.
Key Modifications & Updates
The contract has been significantly modified since its award:
- Modification P00011 (May 4, 2026): Changes the manufacturer from Apotex Inc. to SamChunDang Pharm Co., Ltd. (CMO for Glenmark Therapeutics Inc., USA), updates the place of performance for manufacturing and packaging to Korea, and introduces a new National Drug Code (NDC) effective June 1, 2026. The price per unit remains $10.16.
- Modification P00010 (May 4, 2026): Updates the Point of Contact for Golden State Medical Supply, Inc.
- Modifications P00008, P00006, P00004: Exercised Option Years 3, 2, and 1 respectively, extending the contract's period of performance through February 14, 2027.
- Modification P00007 (January 27, 2026): Implemented changes based on DoD Class Deviation 2025-O0003, revising and deleting various FAR clauses related to equal opportunity, environmental compliance, and sustainable procurement.
- Modification P00005 (January 21, 2025): Incorporated FAR 52.204-30, "Federal Acquisition Supply Chain Security Act Orders-Prohibition," requiring compliance with supply chain security measures.
- Modification P00003 (August 24, 2023): Added Drug Supply Chain Security Act (DSCSA) language to labeling requirements.
- Modification P00002 (August 24, 2023): Incorporated FAR 52.204-27, "Prohibition on a ByteDance Covered Application."
Place of Performance
Initially Canada, the place of performance for manufacturing and packaging is now updated to Korea as per Modification P00011.
Agency & Contacts
- Department: DEPT OF DEFENSE
- Sub-Tier: DEFENSE LOGISTICS AGENCY
- Office: DLA TROOP SUPPORT
- Primary Contact: Kyle Lewicki (kyle.lewicki@dla.mil, 4457370977)
- Secondary Contact: Jason Wray (Jason.wray@dla.mil, 4457376304)